article thumbnail

Medicinal cannabis: Why more clinical trials and better access is needed

Drug Discovery World

Michael Sassano , CEO at SOMAÍ Pharmaceuticals looks at what’s needed throughout Europe to help increase access to medicinal cannabis and the current state of pharmaceutical research in this area. However, the potential use of cannabis in a pharmaceutical setting is vast. The GW Pharmaceuticals purchase by Jazz for $6.7

article thumbnail

Allecra Therapeutics and Shanghai Haini Pharmaceutical Announce Exclusive Licensing Agreement for Cefepime/enmetazobactam for Greater China

The Pharma Data

Allecra, subject to the satisfaction of terms and conditions as set forth in the Exclusive Licensing Agreement, is to receive an upfront cash payment and is eligible to receive additional development and commercial milestone payments with an overall deal value of $78 million, in addition to royalties.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Nvidia invests $50 million into Recursion for drug AI 

Drug Discovery World

NVIDIA will also help optimise and scale Recursion foundation models leveraging the NVIDIA AI stack and NVIDIA’s full-stack computing expertise. “Generative AI is a revolutionary tool to discover new medicines and treatments,” said Jensen Huang, founder and CEO of NVIDIA. “We

Drugs 130
article thumbnail

Highs and lows of drug repurposing 

Drug Discovery World

It’s why pharmaceutical companies will often spend up to 10 years and upwards of $1 billion before receiving regulatory approval for a drug. This is a stark contrast to the often decade-long projects that pharmaceutical companies undertake to bring a drug to market. Global efforts .

article thumbnail

Avacta Announces License Agreement With POINT Biopharma Inc.

The Pharma Data

CAMBRIDGE, England & WETHERBY, England–( BUSINESS WIRE )– Avacta Group plc (AIM: AVCT), the developer of innovative cancer therapies and diagnostics based on its proprietary Affimer ® and pre|CISION platforms, is pleased to announce that it has entered into a license agreement with POINT Biopharma Inc.

article thumbnail

ImaginAb Announces License and Supply Agreement with Pfizer for CD8 ImmunoPET Technology

The Pharma Data

a leading global provider of immuno-oncology imaging agents, today announced it has signed a new multi-year, non-exclusive license with Pfizer Inc. ImaginAb will receive license fees and payments for manufacturing and other support. Working with leading pharmaceutical companies such as Pfizer, will help us achieve our goal.”

article thumbnail

Pfizer and CytoReason collaborate to bolster AI in drug discovery

Drug Discovery World

Pfizer will make a $20 million equity investment, have options to license CytoReason’s platform and disease models, and fund supplementary project support. Pfizer has extended its multi-year partnership with CytoReason to use CytoReason’s artificial intelligence (AI) technology for Pfizer’s drug development programs. .